Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining, normally used to...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Subviral Agents01:29

Subviral Agents

Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gpnmb defines a phagocytic state of microglia linked to cell death in prion disease mouse model.

Nature communications·2026
Same author

Reduced plasma TIA-1: bridging established pathology and novel biomarker potential.

Alzheimer's research & therapy·2026
Same author

A distinct tau oligomer strain defines the molecular and proteomic landscape of rapidly progressive Alzheimer's disease.

Acta neuropathologica·2026
Same author

Detection of alpha-synuclein seeding activity in tear fluid in patients with Parkinson's disease.

NPJ Parkinson's disease·2026
Same author

Therapeutic Potential of Amyloid-β Interactors in Rapidly Progressive Alzheimer's Disease-An In Silico Study.

Molecular informatics·2026
Same author

Alterations in cerebrospinal fluid levels of myelin- and oligodendrocyte-related proteins in sporadic Creutzfeldt-Jakob disease.

Acta neuropathologica communications·2026

Related Experiment Video

Updated: Jul 13, 2026

Investigating the Spreading and Toxicity of Prion-like Proteins Using the Metazoan Model Organism C. elegans
12:57

Investigating the Spreading and Toxicity of Prion-like Proteins Using the Metazoan Model Organism C. elegans

Published on: January 8, 2015

Therapeutic approaches for prion disorders.

Heike Ludewigs1, Chantal Zuber, Karen Vana

  • 1Laboratorium für Molekulare Biologie, Genzentrum, Institut für Biochemie der LMU München, München, Germany. ludewigs@lmb.uni-muenchen.de

Expert Review of Anti-Infective Therapy
|August 7, 2007
PubMed
Summary

Prion diseases, like Creutzfeldt-Jakob disease (CJD), are fatal neurodegenerative disorders lacking effective treatments. This review explores current and emerging therapeutic strategies, including drug delivery systems and vaccination trials, for transmissible spongiform encephalopathies (TSEs).

More Related Videos

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes
10:33

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes

Published on: July 23, 2016

Prion Safety Laboratory Swipe Test
06:01

Prion Safety Laboratory Swipe Test

Published on: February 14, 2025

Related Experiment Videos

Last Updated: Jul 13, 2026

Investigating the Spreading and Toxicity of Prion-like Proteins Using the Metazoan Model Organism C. elegans
12:57

Investigating the Spreading and Toxicity of Prion-like Proteins Using the Metazoan Model Organism C. elegans

Published on: January 8, 2015

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes
10:33

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes

Published on: July 23, 2016

Prion Safety Laboratory Swipe Test
06:01

Prion Safety Laboratory Swipe Test

Published on: February 14, 2025

Area of Science:

  • Neuroscience
  • Infectious Diseases
  • Pharmacology

Background:

  • Prion diseases, including Creutzfeldt-Jakob disease (CJD), are rapidly progressive and fatal neurodegenerative disorders with no available cure.
  • Transmissible spongiform encephalopathies (TSEs) affect both humans and animals, posing significant public health challenges.

Purpose of the Study:

  • To review classical and modern therapeutic strategies for prion disorders.
  • To explore novel drug delivery systems and vaccination trials for anti-prion components.
  • To discuss potential therapeutic targets and challenges in developing TSE treatments.

Main Methods:

  • Comprehensive literature review of clinical trials and preclinical studies on anti-TSE drug development.
  • Analysis of various therapeutic approaches targeting prion protein (PrP) and its receptors.
  • Evaluation of delivery systems like viral vectors for anti-prion agents (e.g., antibodies, siRNAs).

Main Results:

  • No efficient drug is currently available for TSE treatment or cure.
  • Multiple therapeutic strategies are under investigation, targeting PrP(c), PrP(Sc), the 37/67-kDa laminin receptor, and heparan sulfate proteoglycanes.
  • Novel delivery systems and vaccination trials show promise for future anti-prion therapies.

Conclusions:

  • Despite decades of research, effective treatments for prion diseases remain elusive.
  • Advancements in drug delivery and targeting strategies offer hope for future therapeutic breakthroughs.
  • Further research and clinical trials are crucial to overcome hindrances and achieve a breakthrough in prion disorder therapy.